Editorial: Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease

Editorial: Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease–Authors' reply

Published:2023-08-26 Issue:6 Volume:58 Page:638-639
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Gao Feng¹,Byrne Christopher D.²,Targher Giovanni³^ORCID,Zhuo Shuangmu⁴,Zheng Ming‐Hua⁵⁶⁷^ORCID,

Affiliation:

1. Department of Gastroenterology the First Affiliated Hospital of Wenzhou Medical University Wenzhou China

2. Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton and University of Southampton, Southampton General Hospital Southampton UK

3. Section of Endocrinology, Diabetes and Metabolism, Department of Medicine University of Verona Verona Italy

4. School of Science Jimei University Xiamen China

5. MAFLD Research Center, Department of Hepatology The First Affiliated Hospital of Wenzhou Medical University Wenzhou China

6. Institute of Hepatology Wenzhou Medical University Wenzhou China

7. Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province Wenzhou China

Abstract

LINKED CONTENTThis article is linked to Zhan et al papers. To view these articles, visit https://doi.org/10.1111/apt.17635 and https://doi.org/10.1111/apt.17651

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.17660

Reference10 articles.

1. Recent advances in fibrosis assessment for metabolic dysfunction‐associated fatty liver disease

2. AutoFibroNet: A deep learning and multi‐photon microscopy‐derived automated network for liver fibrosis quantification in MAFLD

3. Digital Pathology: Advantages, Limitations and Emerging Perspectives

4. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images

5. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study